1.Efficacy and Safety of Cerebrolysin in Adjuvant Treatment of Acute Cerebral Infarction: A Systematic Review
Rong TANG ; Peiran CHEN ; Lihong XIAO ; Shihong ZHANG ; Zhongping GOU ; Mei LI ; Ping FENG
China Pharmacy 2017;28(30):4233-4237
OBJECTIVE:To evaluate the efficacy and safety of cerebrolysin in adjuvant treatmenut of acute cerebral infarction systematically,and to provide evidence-based reference in clinic.METHODS:Retrieved from SCI,Cochrane Library,EMBase,PubMed,CJFD,VIP and Wanfang Database,RCTs about cerebrolysin combined with routine plan (trial group) vs.routine plan alone or combined with placebo (control group) in adjuvant treatment of acute cerebral infarction were collected.After data extraction and quality evaluation by using Cochrane systematic review manual 5.1.0,Meta-analysis was conducted by using Rev Man 5.2 statistical software.RESULTS:A total of 20 RCTs were included,involving 3 313 patients.Meta-analysis showed that NIHSS score [MD=-1.77,95%CI(-2.33,-1.21),P<0.001],response rate [OR=2.85,95%CI(1.75,4.63),P<0.001] and Barthel index (BI) score [MD =7.30,95 % CI (3.48,11.13),P< 0.001] in trial group were significantly higher than control group,with statistical significance.There was no statistical significance in disability rate [OR=0.46,95% CI(0.20,1.03),P=0.06],mortality [OR=0.79,95% CI (0.52,1.19),P=0.25],the incidence of ADR [OR=1.04,95% CI (0.85,1.27),P=0.72] or the incidence of severe ADR [OR=0.01,95%CI(-0.02,0.04),P=0.51] between 2 groups.CONCLUSIONS:Cerebrolysin is good for adjanctive therapy of acute cerebral infarction,can significantly improve neurologic impairment and life quality and dosen't increase the incidence of ADR.
2.Clinical observation on cervical spondylosis of neck type treated with acupuncture at original and terminal points of trapezius.
Chinese Acupuncture & Moxibustion 2012;32(3):211-214
OBJECTIVETo compare the differences of therapeutic effect of cervical spondylosis of neck type treated with acupuncture at starting and ending points of trapezius and the Jiaji (EX-B 2) points.
METHODSSixty cases of cervical spondylosis of neck type were randomly divided into an observation group and a control group, 30 cases in each group. In observation group, the acupoints related with starting and ending points of trapezius, such as Tianzhu (BL 10), Fengchi (GB 20), Quyuan (SI 13), Jugu (LI 16) and Ashi were punctured; in control group, Jiaji (EX-B 2) points of neck were punctured. The treatments were applied 5 times a week and 2 weeks made one course. The international simplified McGill scale was adoped to assess the scores of Pain Rating Index (PRI), Visual Analogue Scale (VAS) and Present Pain Intensity (PPI) before treatment and after one course treatment, and the therapeutic effects were measured.
RESULTSAfter treatment, all the scores were obviously reduced in both groups: (all P < 0.01), and the PRI-sensory subscore, PRI-affective subscore and total score in observation group reduced more obviously than those in control group, and there were statistically significant differences between groups (all P < 0.01). There were no statistically significant differences between groups in VAS and PPI score (both P > 0.05). The total effective rate of 96.7% (29/30) in observation group was superior to that of 70.0% (21/30) in control group (P < 0.01).
CONCLUSIONThe therapeutic effect of cervical spondylosis of neck type treated with acupuncture at the starting and ending points of trapezius is positive, which is better than that of acupuncture at the Jiaji (EX-B 2) points.
Acupuncture Points ; Acupuncture Therapy ; Adult ; Female ; Humans ; Male ; Middle Aged ; Neck Muscles ; physiopathology ; Spondylosis ; physiopathology ; therapy
3.The comparative research on the surgical treatment result of complex acetabula fracture assisted by 3D printing technology
Qihua QI ; Kunwang BAO ; Qiang XIAO ; Liang DENG ; Cheng LI ; Jihuan ZENG ; Zhongping YUAN ; Xieping DONG
The Journal of Practical Medicine 2018;34(5):750-754
Objective To evaluate the advantage of 3D printing technique in treatment of complicated ace-tabula fracture,we compared the early clinical outcomes of surgical treatment for complex acetabula fracture with traditional surgery(group A)and that assisted by 3D printing technique(group B).Methods A prospective anal-ysis of 35 complicated acetabula fractures was performed at our department,13 patients cured assisted with 3D printing technique. The other 22 patients performed traditional surgery. Surgical trauma,systematic inflammation, immediate reduction effect were evaluated by Matta image assessment standard,and rehabilitation functional status evaluated by Harris score system and Merled' Aubigne and Postel Grading standard. Results There were signifi-cant differences between the two groups regarding intraoperative blood loss,postoperative drainage,operation time (P<0.05),and group B was superior to group A.C reactive protein,leucocyte and creatine kinase MM in periph-eral blood in group A were much higher than those in group B at 24 hours postoperatively(P<0.01).The result of reduction of fracture is poor in group A,but excellent rate of reduction is about 84% in group B. The result of Merled' Aubigne and Postel scores grading was superior in group B(P = 0.013). The excellent and good rate of Harris function score in B group was significantly higher than that in group A(P=0.027).Conclusion The treat-ment of complicated acetabula fracture assisted by 3D printing is excellent in short-term follow up,achieving good reduction with limited trauma,long-term prognosis needs to be further followed up.
4.Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial.
Xiaoyan GE ; Linhua YANG ; Jie JIN ; Wenbin QIAN ; Jianyong LI ; Renchi YANG ; Xiangshan CAO ; Bin JIANG ; Zhao WANG ; Ming HOU ; Weihua ZHANG ; Zhongping XIAO ; Yongqiang ZHAO ; Da GAO ; Xiaohong ZHANG ; Shuye WANG ; Aining SUN ; Jinxiang FU ; Li SU ; Kang LI
Chinese Journal of Hematology 2015;36(7):547-552
OBJECTIVETo evaluate the efficacy and safety of anagrelide in essential thrombocythemia (ET).
METHODSPatients who diagnosed as ET according to the World Health Organization classification were enrolled. Each patient was assigned to take anagrelide hydrochloride capsule or hydroxyurea tablet by random 1∶1 ratio. Dose of anagrelide started at 2 mg/d, then increased gradually and the maximum dose was 10 mg/d until the platelet counts dropped to (100-400) × 10⁹/L, one month later gradually reduced to maintain dose. The dose of hydroxyurea was 1000 mg/d at beginning, then increased gradually, when platelet counts dropped to (100-400)×10⁹/L and kept for one month, reduced to maintain dose as 10 mg·kg⁻¹·d⁻¹. The observation period was 12 weeks.
RESULTSA total of 222 patients were enrolled in seventeen centers (including 113 patients treated with anagrelide and 109 with hydroxyurea). Therapy efficacy can be evaluated in 198 patients (including 97 patients administered with anagrelide and 101 with hydroxyurea). At 12th weeks of therapy, the hematologic remission rate was 87.63% (85/97) in anagrelide group and 88.12% (89/107) in hydroxyurea group, the differences between the two groups were not significant (P=0.173). Treatment with anagrelide lowered the platelet counts by a median of 393 (362-1 339) × 10⁹/L from a median of 827 (562-1657) × 109/L at the beginning of the observation to 400(127-1130)×10⁹/L after 12 weeks (P<0.001), which were similar to the treatment result of hydroxyurea by a median drop of 398 (597-1846)× 10⁹/L (P=0.982). The median time to achieving response of anagrelide group was 7 (3-14) days, superior to that of hydroxyurea for 21 (14-28) significantly (P=0.003). Frequency of anagrelide related adverse events was 65.49 % (74/113), including cardiopalmus (36.28% ), headache (21.24% ), fatigue (14.16% ) and dizzy (11.50% ).
CONCLUSIONAnagrelide was effective in patients with ET which had similar hematologic remission rate to hydroxyurea and could take effect more quickly than hydroxyurea. Incidence of adverse events was undifferentiated between anagrelide and hydroxyurea, but anagrelide treatment had tolerable adverse effects and no hematologic toxicity.
Humans ; Hydroxyurea ; administration & dosage ; therapeutic use ; Platelet Aggregation Inhibitors ; administration & dosage ; therapeutic use ; Platelet Count ; Quinazolines ; administration & dosage ; therapeutic use ; Thrombocythemia, Essential ; drug therapy ; Treatment Outcome
5.Correlation between serological screening of human T-lymphotropic virus antibodies and confirmatory tests
Yanqing DENG ; Hao WANG ; Zhengang SHAN ; Junmou XIE ; Rongsong DU ; Xunnan XIAO ; Zhongping LI ; Xia RONG ; Boquan HUANG
Chinese Journal of Blood Transfusion 2023;36(11):1022-1025
【Objective】 To explore the correlation between serological screening of human T-lymphotropic virus antibodies (anti HTLV) and Western blot(WB) confirmatory tests among blood donors, so as to explore the infection status of HTLV Ⅰ/Ⅱ in Guangzhou. 【Methods】 The anti HTLV Ⅰ/Ⅱ enzyme-linked immunosorbent assay(ELISA) kit was used to screen voluntary blood donors from Guangzhou Blood Center from July 2016 to August 2022. WB was used to confirm 395 reactive blood samples by ELISA. The correlation between the S/CO values of anti HTLV Ⅰ/Ⅱ ELISA reagents and the confirmatory test was analyzed using ROC curves. 【Results】 The results showed that 25 out of 395 initially screened reactive blood donor samples were confirmed as HTLV positive by WB, while 16 were uncertain. ROC curve analysis showed a correlation between the S/CO values by ELISA and the confirmatory test results: the S/CO value at the highest Youden index was 3.789, which was the optimal threshold. The S/CO value had a certain correlation with the predicted positive rate of confirmatory results (P<0.05): the larger the S/CO value, the higher the predicted positive value. The overall prevalence of HTLV in Guangzhou is relatively low. 【Conclusion】 The prevalence of HTLV among blood donors in Guangzhou is low.Since the false positive rate of HTLV Ⅰ/Ⅱ antibody by ELISA serological screening is high, the confirmatory testing is particularly important.
6.Interpretation of the essential updates in guidelines for the prevention and treatment of chronic hepatitis B (Version 2022).
Hong YOU ; Ya Meng SUN ; Meng Yang ZHANG ; Yue Min NAN ; Xiao Yuan XU ; Tai Sheng LI ; Gui Qiang WANG ; Jin Lin HOU ; Zhongping DUAN ; Lai WEI ; Fu Sheng WANG ; Ji Dong JIA ; Hui ZHUANG
Chinese Journal of Hepatology 2023;31(4):385-388
Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association update the guidelines for the prevention and treatment of chronic hepatitis B (version 2022) in 2022. The latest guidelines recommend more extensive screening and more active antiviral treating for hepatitis B virus infection. This article interprets the essential updates in the guidelines to help deepen understanding and better guide the clinical practice.
Humans
;
Hepatitis B, Chronic/drug therapy*
;
Hepatitis B/drug therapy*
;
Hepatitis B virus
;
Antiviral Agents/therapeutic use*
;
Gastroenterology